IMPACT results show potential cancer treatment

Apr 19, 2010

Dr. Neal Shore (GB) presented for the first time in Europe the updated results of the study "Sipuleucel-T Active Cellular Immunotherapy for Metastatic, Castration-Resistant Prostate Cancer: results from the IMPACT trial," during the second plenary session of the 25th Anniversary EAU Congress in Barcelona.

"This study shows a potential new treatment paradigm in oncology and is the first active to demonstrate improvement in overall survival (OS) for metastatic CRPC (castrate-resistant prostate cancer)," said Shore

Shore said the effect was upheld with longer follow-up and that the majority of the most common adverse events occurred within one day of infusion, were mild and moderate in severity ( < grade 2) and resolved within one to two days.

"Response rate and time to progression may not be appropriate endpoints in therapeutic vaccine trials," Shore said, adding that the use of immune therapy earlier in the natural history of the disease requires further study.

Sipuleucel-T is an investigational autologous active cellular immunotherapy for treatment of . The randomised, double-blind, placebo controlled phase III trial in CRPC showed a significant increase in OS. Adverse events reported more commonly in the sipuleucel-T than the placebo arm included chills, pyrexia, headache, influenza- like illness, myalgia, hypertension, hyperhidrosis and groin pain.

Other findings indicate that prognostic factors were well-balanced with the median predicted OS of patients in the sipuleucel-T and placebo arms were 20.3 and 21.2 months, respectively, using the Halabi model (2003).

Explore further: Prosocial internet support group not beneficial for breast cancer

Provided by European Association of Urology

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Prostate cancer vaccines more effective with hormone therapy

Jul 10, 2008

Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.